Idiopathic Thrombocytopenic Purpura Therapeutics Market Size

The global idiopathic thrombocytopenic purpura therapeutics market is expected to reach USD 914.9 million by 2030, expanding at a CAGR of 5.0% from 2023 to 2030. Rising R&D leading to the introduction of new drugs for IVIG and TPO-RA classes is expected to propel growth over the forecast period. In addition, government regulation such as the Orphan Drug Act in the United States with an aim to encourage new product development is projected to fuel growth.

The industry is characterized by a rising demand for combination therapies as they exhibit higher efficiency as compared to other treatments. Moreover, they are cost-efficient and help curb side effects associated with individual therapeutic classes. Some of the major combination therapies are dexamethasone and rituximab, dexamethasone and TPO-RA, IVIG, and corticosteroids. Splenectomy, the procedure to remove the spleen is aimed at reducing the amount of anti-platelet antibodies, is expected to fuel demand. Corticosteroids are regularly used in idiopathic thrombocytopenic purpura treatment. Since corticosteroid are considered to be the first line of therapy for patients suffering from ITP, the usage rates of corticosteroid are very high.

Idiopathic Thrombocytopenic Purpura Therapeutics Market Report Highlights

TPO-RA is likely to witness substantial growth, growing at a CAGR of over 6.6% from 2023 to 2030 owing to high response rates exhibited by patients administered with Eltrombopag and Romiplostim. Moreover, demand for TPO-RA is expected to increase due to the commercialization of Avatrombopag in 2015. In addition, the ability of TPO-RA to cater to splenectomized patients witnessing relapses is expected fuel demand over the next six years.
North America dominated the market and accounted for the largest revenue share of 39.9% in 2022.
Asia Pacific is expected to grow at the fastest CAGR of 6.2% over the forecast period.
Asia Pacific is expected to experience substantial growth over the next six years, owing to the presence of favorable government initiatives, and sophisticated healthcare infrastructure in Australia and Japan. In addition, the presence of vast untapped opportunities in emerging markets such as China and India is expected to propel growth.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.1.1. Disease Type
1.1.2. Product
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease type outlook
2.2.2. Product outlook
2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Idiopathic Thrombocytopenic Purpura Therapeutics Market Variables, Trends & Scope

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Idiopathic Thrombocytopenic Purpura Therapeutics Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape

Chapter 4. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Disease Type Estimates & Trend Analysis

4.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Disease Type Key Takeaways
4.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Acute ITP
4.3.1. Acute ITP market estimates and forecasts, 2018 to 2030, (USD Million)
4.4. Chronic
4.4.1. Chronic market estimates and forecasts, 2018 to 2030, (USD Million)
4.5. Others
4.5.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Product Estimates & Trend Analysis

5.1. Idiopathic Thrombocytopenic Purpura Therapeutics Market, By Product Key Takeaways
5.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Corticosteroids
5.3.1. Corticosteroids market estimates and forecasts, 2018 to 2030, (USD Million)
5.4. IVIG
5.4.1. IVIG market estimates and forecasts, 2018 to 2030, (USD Million)
5.5. Anti-D Immunoglobulins
5.5.1. Anti-D Immunoglobulins market estimates and forecasts, 2018 to 2030, (USD Million)
5.6. TPO-RA
5.6.1. TPO-RA market estimates and forecasts, 2018 to 2030, (USD Million)
5.7. Others
5.7.1. Others market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 6. Idiopathic Thrombocytopenic Purpura Therapeutics Market: Regional Estimates & Trend Analysis

6.1. Regional Outlook
6.2. Idiopathic Thrombocytopenic Purpura Therapeutics Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. U.K.
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.2.1. Amgen Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Disease Type benchmarking
7.2.1.4. Strategic initiatives
7.2.2. F. Hoffmann-La Roche Ltd
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Disease Type benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Grifols, S.A.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Disease Type benchmarking
7.2.3.4. Strategic initiatives
7.2.4. GSK plc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Disease Type benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Shangxian Minimal Invassive Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Disease Type benchmarking
7.2.5.4. Strategic initiatives
7.2.6. INTROMEDIC
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Disease Type benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Medtronic
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Disease Type benchmarking
7.2.7.4. Strategic initiatives
7.2.8. FUJIFILM Holdings Corporation
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Disease Type benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Olympus Corporation
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Disease Type benchmarking
7.2.9.4. Strategic initiatives
7.2.10. JINSHAN Science & Technology (Group) Co., Ltd.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Disease Type benchmarking
7.2.10.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 3 North America idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 4 North America idiopathic thrombocytopenic purpura therapeutics market, by country, 2018-2030 (USD Million)
Table 5 U.S. idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 6 U.S. idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 7 Canada idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 8 Canada idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 9 Europe idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 10 Europe idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 11 Europe idiopathic thrombocytopenic purpura therapeutics market, by country, 2018-2030 (USD Million)
Table 12 Germany idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 13 Germany idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 14 UK idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 15 UK idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 16 France idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 17 France idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 18 Italy idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 19 Italy idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 20 Spain idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 21 Spain idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 22 Denmark idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 23 Denmark idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 24 Sweden idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 25 Sweden idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 26 Norway idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 27 Norway idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 28 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 29 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 30 Asia Pacific idiopathic thrombocytopenic purpura therapeutics market, by country, (USD Million) 2018-2030
Table 31 Japan idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 32 Japan idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 33 China idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 34 China idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 35 India idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 36 India idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 37 Thailand idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 38 Thailand idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 39 South Korea idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 40 South Korea idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 41 Latin America idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 42 Latin America idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 43 Latin America idiopathic thrombocytopenic purpura therapeutics market, by country, 2018-2030 (USD Million)
Table 44 Brazil idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 45 Brazil idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 46 Mexico idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 47 Mexico idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 48 Argentina idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 49 Argentina idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 50 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 51 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 52 Middle East and Africa idiopathic thrombocytopenic purpura therapeutics market, by country, (USD Million) 2018-2030
Table 53 Saudi Arabia idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 54 Saudi Arabia idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 55 South Africa idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 56 South Africa idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 57 UAE idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 58 UAE idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)
Table 59 Kuwait idiopathic thrombocytopenic purpura therapeutics market, by disease type, 2018-2030 (USD Million)
Table 60 Kuwait idiopathic thrombocytopenic purpura therapeutics market, by product, 2018-2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Idiopathic thrombocytopenic purpura therapeutics: market outlook
Fig. 9 Idiopathic thrombocytopenic purpura therapeutics competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Idiopathic thrombocytopenic purpura therapeutics market driver impact
Fig. 15 Idiopathic thrombocytopenic purpura therapeutics market restraint impact
Fig. 16 Idiopathic thrombocytopenic purpura therapeutics market strategic initiatives analysis
Fig. 17 Idiopathic thrombocytopenic purpura therapeutics market: Disease type movement analysis
Fig. 18 Idiopathic thrombocytopenic purpura therapeutics market: Disease type outlook and key takeaways
Fig. 19 Acute ITP market estimates and forecasts, 2018-2030 (USD Million)
Fig. 20 Chronic market estimates and forecasts, 2018-2030 (USD Million)
Fig. 21 Others market estimates and forecasts, 2018-2030 (USD Million)
Fig. 22 Idiopathic thrombocytopenic purpura therapeutics market: Product type movement analysis
Fig. 23 Idiopathic thrombocytopenic purpura therapeutics market: Product type outlook and key takeaways
Fig. 24 OGIB market estimates and forecasts, 2018-2030 (USD Million)
Fig. 25 IVIG market estimates and forecasts, 2018-2030 (USD Million)
Fig. 26 Anti-D immunoglobulins market estimates and forecasts, 2018-2030 (USD Million)
Fig. 27 TPO-RA market estimates and forecasts, 2018-2030 (USD Million)
Fig. 28 Others market estimates and forecasts, 2018-2030 (USD Million)
Fig. 29 Global idiopathic thrombocytopenic purpura therapeutics market: Regional movement analysis
Fig. 30 Global idiopathic thrombocytopenic purpura therapeutics market: Regional outlook and key takeaways
Fig. 31 North America market estimates and forecasts, 2018-2030 (USD Million)
Fig. 32 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Fig. 33 Canada market estimates and forecasts, 2018-2030 (USD Million)
Fig. 34 Europe market estimates and forecasts, 2018-2030 (USD Million)
Fig. 35 UK market estimates and forecasts, 2018-2030 (USD Million)
Fig. 36 Germany market estimates and forecasts, 2018-2030 (USD Million)
Fig. 37 France market estimates and forecasts, 2018-2030 (USD Million)
Fig. 38 Italy market estimates and forecasts, 2018-2030 (USD Million)
Fig. 39 Spain market estimates and forecasts, 2018-2030 (USD Million)
Fig. 40 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Fig. 41 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Fig. 42 Norway market estimates and forecasts, 2018-2030 (USD Million)
Fig. 43 Asia Pacific market estimates and forecasts, 2018-2030 (USD Million)
Fig. 44 Japan market estimates and forecasts, 2018-2030 (USD Million)
Fig. 45 China market estimates and forecasts, 2018-2030 (USD Million)
Fig. 46 India market estimates and forecasts, 2018-2030 (USD Million)
Fig. 47 Australia market estimates and forecasts, 2018-2030 (USD Million)
Fig. 48 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Fig. 49 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Fig. 50 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Fig. 51 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Fig. 52 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Fig. 53 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Fig. 54 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Fig. 55 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Fig. 56 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Fig. 57 UAE market estimates and forecasts, 2018-2030 (USD Million)
Fig. 58 Kuwait market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

Amgen Inc.
F. Hoffmann-La Roche Ltd
Grifols, S.A.
GSK plc.
Shangxian Minimal Invassive Inc.
INTROMEDIC
Medtronic
FUJIFILM Holdings Corporation
Olympus Corporation
JINSHAN Science & Technology (Group) Co., Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	60
Published	October 2023
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 622.6 Million
Forecasted Market Value ( USD ) by 2030	$ 914.9 Million
Compound Annual Growth Rate	5.0%
Regions Covered	Global
No. of Companies Mentioned	10

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5911EUR$5,950USD£4,915GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6904EUR$6,950USD£5,741GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8891EUR$8,950USD£7,393GBP

Idiopathic Thrombocytopenic Purpura Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Corticosteroids, IVIG, Anti-D Immunoglobulins, TPO-RA, Others), By Region, And Segment Forecasts, 2023 - 2030

Idiopathic Thrombocytopenic Purpura Therapeutics Market Report Highlights

Table of Contents

Companies Mentioned

Methodology

Table Information

Idiopathic Thrombocytopenic Purpura Therapeutics Market Report Highlights

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Immune Thrombocytopenic Purpura Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

Idiopathic Thrombocytopenic Purpura - Market Insight, Epidemiology and Market Forecast - 2034

Idiopathic Thrombocytopenic Purpura - Pipeline Insight, 2024

Idiopathic Thrombocytopenic Purpura Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Acquired Orphan Blood Diseases Therapeutics Market Report by Therapy, Disease Indication, Distribution Channel, and Region 2024-2032

About the Idiopathic Thrombocytopenic Purpura Drugs Market